News and Announcements
Parkway Minerals (ASX: PWN) Raises $500,000 to support Davenport Resources
- Published June 28, 2018 12:00AM UTC
- Publisher Wholesale Investor
- Categories Company Updates
Parkway Minerals has completed and raised $500000 via a private placement of approximately 50 million shares at $0.01 each. There are two tranches to the placement. The first will see 50 million shares issued at the end of June 2018, which does not require shareholder approval. The second will see approximately 50 million options issued subject to shareholder approval following an August meeting. Each share will have an attached free option. The options are will be issued subject to shareholders approval and will be exercisable at $0.02 and expire after two years from the date of approval.
Parkway Minerals will use the funds to participate in a placement by Davenport Resources. Davenport is a mineral exploration company is having success at its South Harz potash project in Germany. They recently raised $2.1m, and Parkway has been allocated 7.1 million shares and will hold 32% of Davenports issues shares following the transaction. Parkway supports Davenports plans to use funds to fast-track the conversion of significant drilling information to a JORC compliant resource and to identify further drill targets and help Davenport establish Europe’s largest undeveloped potato inventory.
About Parkway Minerals (ASX: PWN)
Focused on fertiliser feedstocks, both potash and phosphates. Projects are large, promising long-term supply within regions that are currently importing their fertiliser needs. The company has exploration assets at different stages of maturity, from early stage to feasibility, and an active programme to develop them. Parkway has cash plus shares valued at $4M.
Company Updates
500 Million Episodes, Limited Treatment: How Patrys is Bridging the Gap in an Underserved Market
In the clinical vocabulary of the Intensive Care Unit, there is perhaps no word that carries as much quiet dread as delirium. It is a “chemical storm” of the brain—an acute dysfunction where the delicate balance between calming and activating signals is scrambled. For the patient, it can be a waking nightmare of hallucinations and […]
The Light Fantastic: Why Invion’s Photodynamic Therapy May Be Attracting Big Pharma’s Attention
Invion Limited is challenging the status quo in oncology with its Photosoft™ platform, a precision therapy that uses light-activated molecules to selectively target cancer cells. By transforming the body’s own immune response and addressing the high costs of current cancer treatments, Invion is positioning itself as a transformative player in the biotech sector. With clinical trials underway and strong institutional partnerships, the company is bridging the gap between scientific breakthrough and accessible, scalable patient care.
From Outback to Boardroom: How SWAN Systems is Codifying Water Stewardship
From the arid deserts of Australia to the boardrooms of global tech giants, SWAN Systems is redefining water efficiency. By bridging the gap between field-level agronomics and autonomous irrigation control, the company is proving that “water-positive” targets can be met with science, data, and a 10x ROI commitment.
Backed By Leading Investment Groups and Family Offices
